esc

Type at least two characters to start searching.

↑↓ select↵ openesc close

Share

Export Citation

APA
MLA
Chicago
Harvard
Vancouver
BIBTEX
RIS
Universitas Hasanuddin
Research output:Contribution to journal›Article›peer-review

Regenerative agents versus autogenous bone graft for alveolar cleft reconstruction: a systematic review and network meta-analysis

Hendrawan M.I.

Archives of Craniofacial Surgery

Q2
Published: 2026

Abstract

BACKGROUND: Autogenous iliac crest bone graft is the standard for alveolar cleft reconstruction, but donor-site morbidity has prompted interest in regenerative agents. This review compared and ranked these agents against autogenous bone and one another. METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for network meta-analyses, six databases were searched from January 2000 to June 2026 for controlled studies comparing a regenerative agent with autogenous bone graft. Risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials and the ROBINS-I tool; certainty was assessed using Grading of Recommendations Assessment, Development and Evaluation. A frequentist random-effects network meta-analysis used autogenous bone as the reference and P-scores to rank treatments for new bone formation, bone density, graft volume, and graft success. RESULTS: Twenty-one studies (23 reports) were included. Platelet-rich fibrin (risk ratio [RR], 1.46; 95% confidence interval [CI], 1.07-2.01) and concentrated growth factor (RR, 1.21; 95% CI, 1.02-1.43) were superior to autograft for graft success; platelet-rich fibrin ranked first (P-score, 0.87) and exceeded recombinant human bone morphogenetic protein-2 (RR, 1.44; 95% CI, 1.04-1.99). In one trial, bone marrow aspirate concentrate increased graft volume (standardized mean difference, 2.36; 95% CI, 1.51-3.21). No agent increased new bone formation or bone density. Certainty was moderate for one comparison, low for six, and very low for nine. CONCLUSION: Autogenous bone remains the volumetric reference standard. The improvement in graft success with platelet-rich fibrin was supported by moderate-certainty evidence and persisted across all sensitivity analyses, including restriction to randomized evidence. The concentrated growth factor finding had low certainty, relied on one retrospective study, and did not persist when analyses were restricted to radiographic outcomes. Adequately powered randomized trials with standardized methods are needed.

Access to Document

10.7181/acfs.2026.0106

Other files and links

Fingerprint

MedicineSciences
Iliac crestSciences
SurgerySciences
FibrinSciences
Randomized controlled trialSciences
Fibrin glueSciences
Fibrin Tissue AdhesiveSciences
DentistrySciences
Confidence intervalSciences
Bone morphogenetic proteinSciences
Bone healingSciences
Bone resorptionSciences
Bone morphogenetic protein 2Sciences
Dental alveolusSciences
Clinical trialSciences
Meta-analysisSciences
Bone marrowSciences
Bone graftingSciences
ResorptionSciences
Bone transplantationSciences